Early-Stage Breast Cancer, EGFR-Mutated NSCLC, and High-Risk Melanoma: 2023 ASCO Annual Meeting Highlights for the Advanced Practitioner

Abstract

Lisa Kottschade, APRN, MSN, CNP, FAPO, of Mayo Clinic, discusses encouraging results of a trial examining adjuvant ribociclib plus estrogen therapy in patients with stage II or III HR+/HER2− early breast cancer. She also discusses the use of the novel mRNA-4157 vaccine in combination with pembrolizumab as adjuvant therapy for resected high-risk melanoma. Finally, she analyzes the overall survival data reported in the ADAURA trial, which demonstrated a statistically significant disease-free and overall survival benefit for patients with EGFR-mutated stage IB to IIIA non–small cell lung cancer.